Contact:
sales@biotechnologyforums.com to feature here

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Engineered "Twincretin" peptide containing both GLP-1 and GIP sequences reduces obesi
#1
Wink 
A recent study in Science Translational Medicine* describes the development and testing of a potential new therapeutic for treating obesity and diabetes. The therapeutic peptide (which was playfully termed "Twincretin"), was engineered by combining sequences from the incretin peptide hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The resulting peptide was subsequently engineered with a PEGylation modification to enhance pharmacokinetics.


Need PEGylated peptides for incretin therapeutics or other peptide-based diabetes/obesity drug candidates? Try GenScript's peptide synthesis service.


GLP-1 has previously been the focus of incretin therapies, due to its ability to suppress appetite, which results in weight loss, and its agonistic effect on the GLP-1 receptor which leads to increased β cell (cells that secrete insulin) survival and proliferation. Overexpression of GIP has been shown to improve body weight and glycemic control. Administration of the twincretin peptide resulted in weight loss in mice and was shown to be more effective than treatment with either peptide alone. In additional experiments, the insulinotropic effect of the twincretin peptide in mice was shown to be translatable to monkeys and humans.
Like Post Reply
  


Messages In This Thread
Engineered "Twincretin" peptide containing both GLP-1 and GIP sequences reduces obesi - by GenscriptUSA - 12-12-2013, 02:26 PM



Users browsing this thread:
1 Guest(s)

Engineered "Twincretin" peptide containing both GLP-1 and GIP sequences reduces obesi00